Zai Lab Limited (ZLAB)
Pre-market:
| Previous close | 50.58 |
| Open | 48.94 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 900 |
| Day's range | 44.45 - 50.02 |
| 52-week range | 44.45 - 187.46 |
| Volume | |
| Avg. volume | 644,720 |
| Market cap | 4.89B |
| Beta (5Y monthly) | 1.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.25 |
| Earnings date | 01 Mar 2022 - 06 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 178.07 |
- Simply Wall St.
We're Not Very Worried About Zai Lab's (NASDAQ:ZLAB) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer
SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced treatment of the first patient in Greater China in the PANOVA-3 trial, a Phase 3 pivotal trial of Tumor Treating Fields in patients with pancreatic cancer. “Pancreatic cancer is a common, highly aggressive form of gastrointestinal cancer, with an estimated five-year survival
- GlobeNewswire
Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for margetuximab, an investigational, Fc-engineered monoclonal antibody that targets HER2. The margetuximab NDA is for the treatment of adult patients with metastatic
